104 related articles for article (PubMed ID: 25738754)
21. Osteoblasts stimulate osteoclastogenesis via RANKL expression more strongly than periodontal ligament cells do in response to PGE(2).
Mayahara K; Yamaguchi A; Takenouchi H; Kariya T; Taguchi H; Shimizu N
Arch Oral Biol; 2012 Oct; 57(10):1377-84. PubMed ID: 22884709
[TBL] [Abstract][Full Text] [Related]
22. Spontaneous osteoclastogenesis is a predictive factor for bone metastases from non-small cell lung cancer.
Roato I; Gorassini E; Buffoni L; Lyberis P; Ruffini E; Bonello L; Baldi I; Ciuffreda L; Mussa A; Ferracini R
Lung Cancer; 2008 Jul; 61(1):109-16. PubMed ID: 18061306
[TBL] [Abstract][Full Text] [Related]
23. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
24. Naringenin inhibits human osteoclastogenesis and osteoclastic bone resorption.
La VD; Tanabe S; Grenier D
J Periodontal Res; 2009 Apr; 44(2):193-8. PubMed ID: 18705650
[TBL] [Abstract][Full Text] [Related]
25. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
26. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
[TBL] [Abstract][Full Text] [Related]
27. Dental cells express factors that regulate bone resorption.
Rani CS; MacDougall M
Mol Cell Biol Res Commun; 2000 Mar; 3(3):145-52. PubMed ID: 10860862
[TBL] [Abstract][Full Text] [Related]
28. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
29. Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E(2) and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells.
Coetzee M; Haag M; Kruger MC
J Nutr Biochem; 2007 Jan; 18(1):54-63. PubMed ID: 16650751
[TBL] [Abstract][Full Text] [Related]
30. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
31. Nicotine and lipopolysaccharide stimulate the formation of osteoclast-like cells by increasing macrophage colony-stimulating factor and prostaglandin E2 production by osteoblasts.
Tanaka H; Tanabe N; Shoji M; Suzuki N; Katono T; Sato S; Motohashi M; Maeno M
Life Sci; 2006 Mar; 78(15):1733-40. PubMed ID: 16266722
[TBL] [Abstract][Full Text] [Related]
32. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
33. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
34. Protein phosphatase 2A Cα is involved in osteoclastogenesis by regulating RANKL and OPG expression in osteoblasts.
Okamura H; Yang D; Yoshida K; Haneji T
FEBS Lett; 2013 Jan; 587(1):48-53. PubMed ID: 23183242
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer cells interact with osteoblasts to support osteoclast formation.
Thomas RJ; Guise TA; Yin JJ; Elliott J; Horwood NJ; Martin TJ; Gillespie MT
Endocrinology; 1999 Oct; 140(10):4451-8. PubMed ID: 10499498
[TBL] [Abstract][Full Text] [Related]
36. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
37. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
38. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
[TBL] [Abstract][Full Text] [Related]
39. The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts.
Persson E; Lerner UH
J Cell Biochem; 2011 Dec; 112(12):3732-41. PubMed ID: 21815197
[TBL] [Abstract][Full Text] [Related]
40. Influence of baicalin on the expression of receptor activator of nuclear factor-kappaB ligand in cultured human periodontal ligament cells.
Wang GF; Wu ZF; Wan L; Wang QT; Chen FM
Pharmacology; 2006; 77(2):71-7. PubMed ID: 16636611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
